Aldeyra Therapeutics, Inc. - Special Call Transcript
Good morning. Thank you all for coming. It is gratifying to see so many of you here and to see how this conference has -- this meeting has grown over the years. We're very appreciative of all our buy-side and sell-side colleagues. I can tell you for certain that those of us at Aldeyra are working very hard on your behalf every day.
I read something about Aldeyra recently that I want to affirm. It is not our intent to build a small company. It is not our intent to launch only one drug. It is not our intent to develop only one molecule or only one mechanism of action. However, our process for growth and adding to our pipeline is deliberate. It is systematic. It is a product of a well-defined and, I think, thoughtful and purposeful rubric. And today, our Chief Commercial Officer, Dave McMullin, will talk to you about how we think about adding to our pipeline and growing our R&D engine.
Our latest acquisition of Helio Vision fits perfectly within that rubric, and we're so thrilled to have Dr. Dean Eliott from
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
